CytomX Therapeutics
CTMX
81 hedge funds and large institutions have $57.2M invested in CytomX Therapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 21 reducing their positions, and 16 closing their positions.
9% more capital invested
Capital invested by funds: $52.6M → $57.2M (+$4.61M)
4% more call options, than puts
Call options by funds: $56K | Put options by funds: $54K
0.57% less ownership
Funds ownership: 55.03% → 54.45% (-0.57%)
5% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 21
4% less funds holding
Funds holding: 84 → 81 (-3)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.76M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$605K |
| 3 |
Two Sigma Investments
New York
|
+$566K |
| 4 |
D.E. Shaw & Co
New York
|
+$190K |
| 5 |
CM
CM Management
Gulf Breeze,
Florida
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$878K |
| 2 |
BlackRock
New York
|
-$739K |
| 3 |
Renaissance Technologies
New York
|
-$688K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$640K |
| 5 |
E
Ergoteles
New York
|
-$405K |
CTMX Hedge Fund Activity: Q4 2022 in Review
81 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2022, worth a combined $57.2M — up 8.8% from $52.6M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CTMX and 13 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 20 added.
The largest buyer was Millennium Management, adding an estimated $1.76M. The largest seller was Platinum Investment Management, cutting an estimated $878K.
- 81 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2022, down from 84 in Q3 2022.
- Funds reported $57.2M of CytomX Therapeutics stock for Q4 2022, up 8.8% quarter-over-quarter.
- 13 funds opened new CytomX Therapeutics positions in Q4 2022 and 16 closed out, a net change of -3 holders.
- The largest CytomX Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $1.76M added.
- The largest CytomX Therapeutics seller in Q4 2022 was Platinum Investment Management, an estimated $878K sold.
Based on aggregated 13F filings for Q4 2022.